Press Releases
Alexion Pharma (ALXN) Granted Ophand Drug Status in Europe for ALXN1210
Alexion Pharmaceuticals Inc announced that the EC as granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting C5 antibody being evaluated in...
Research Insight
Mylan Launches First Generic of Nuvigil Tablets
Mylan N.V. announced the U.S. launch of Armodafinil Tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephalon's Nuvigil®. Mylan received final...
Press Releases
EC Approves the AbbVies IMBRUVICA for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
AbbVie a global biopharmaceutical company announced that the EC approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia...
News
Otsuka Holdings Announces New, Additional Certification Under “ISO 22301” (International Standard for Business Continuity Management)
Expands scope of certification to include additional Otsuka Group products, reflecting the company’s improved resiliency and continuous operational capability during unexpected events. ...
Press Releases
Allergan Receives FDA Approval of TEFLARO for Pediatric Patients
Label Now Includes New Data on Use of TEFLARO in Pediatric Patients 2 Months of Age to Less than 18 Years of Age...
Press Releases
EU Grants Approval to Remicade Biosimilar Flixabi
The European Commission (EC) granted marketing authorization in the European Union (EU) for FLIXABI®, an infliximab biosimilar referencing Remicade®i. FLIXABI was developed by Samsung...
Clinical Trials
Positive VIMPAT monotherapy Phase III trial results presented at European Academy of Neurology Congress
Trial further highlights UCB’s longstanding commitment to enhancing value for people living with epilepsy Data submitted to EMA earlier this year to extend...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read